Neumora Therapeutics Inc [NMRA] stock is trading at $1.80, up 5.26%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NMRA shares have gain 6.51% over the last week, with a monthly amount drifted -13.46%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neumora Therapeutics Inc [NASDAQ: NMRA] stock has seen the most recent analyst activity on January 02, 2025, when RBC Capital Mkts downgraded its rating to a Sector Perform and also revised its price target to $4 from $29. Previously, JP Morgan downgraded its rating to Neutral on November 05, 2024, and dropped its price target to $15. On October 01, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $30 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $23 on July 22, 2024. Mizuho initiated its recommendation with a Outperform and recommended $20 as its price target on July 08, 2024. Deutsche Bank started tracking with a Hold rating for this stock on December 12, 2023, and assigned it a price target of $13. In a note dated October 10, 2023, William Blair initiated an Outperform rating and provided a target price of $26 on this stock.
Neumora Therapeutics Inc [NMRA] stock has fluctuated between $1.60 and $21.00 over the past year. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Neumora Therapeutics Inc [NASDAQ: NMRA] shares were valued at $1.80 at the most recent close of the market. An investor can expect a potential return of 122.22% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.83, Equity is -0.74 and Total Capital is -0.98. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7033 points at the first support level, and at 1.6067 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8633, and for the 2nd resistance point, it is at 1.9267.
Ratios To Look Out For
For context, Neumora Therapeutics Inc’s Current Ratio is 10.98. Further, the Quick Ratio stands at 10.98, while the Cash Ratio is 8.69.
Transactions by insiders
Recent insider trading involved BERNS PAUL L, that happened on Feb 18 ’25 when 13871.0 shares were sold. Milligan Michael Lee completed a deal on Feb 18 ’25 to sell 1978.0 shares. Meanwhile, Chief Strategy Officer Aurora Daljit Singh sold 8565.0 shares on Feb 18 ’25.
